206 related articles for article (PubMed ID: 36854172)
1. Photoinduced Reduction of Novel Dual-Action Riboplatin Pt(IV) Prodrug.
Krasnovskaya OO; Akasov RA; Spector DV; Pavlov KG; Bubley AA; Kuzmin VA; Kostyukov AA; Khaydukov EV; Lopatukhina EV; Semkina AS; Vlasova KY; Sypalov SA; Erofeev AS; Gorelkin PV; Vaneev AN; Nikitina VN; Skvortsov DA; Ipatova DA; Mazur DM; Zyk NV; Sakharov DA; Majouga AG; Beloglazkina EK
ACS Appl Mater Interfaces; 2023 Mar; 15(10):12882-12894. PubMed ID: 36854172
[TBL] [Abstract][Full Text] [Related]
2. Light-Responsive Pt(IV) Prodrugs with Controlled Photoactivation and Low Dark Toxicity.
Spector D; Bubley A; Zharova A; Bykusov V; Skvortsov D; Ipatova D; Erofeev A; Gorelkin P; Vaneev A; Mazur D; Nikitina V; Melnikov M; Pergushov V; Bunin D; Kuzmin V; Kostyukov A; Egorov A; Beloglazkina E; Akasov R; Krasnovskaya O
ACS Appl Bio Mater; 2024 May; 7(5):3431-3440. PubMed ID: 38697834
[TBL] [Abstract][Full Text] [Related]
3. An upconversion nanoplatform for simultaneous photodynamic therapy and Pt chemotherapy to combat cisplatin resistance.
Ai F; Sun T; Xu Z; Wang Z; Kong W; To MW; Wang F; Zhu G
Dalton Trans; 2016 Aug; 45(33):13052-60. PubMed ID: 27430044
[TBL] [Abstract][Full Text] [Related]
4. An Anticancer Pt
Kostrhunova H; Petruzzella E; Gibson D; Kasparkova J; Brabec V
Chemistry; 2019 Apr; 25(20):5235-5245. PubMed ID: 30740808
[TBL] [Abstract][Full Text] [Related]
5. Electrochemical Detection of a Novel Pt(IV) Prodrug with the Metronidazole Axial Ligand in the Hypoxic Area.
Spector DV; Erofeev AS; Gorelkin PV; Vaneev AN; Akasov RA; Ul'yanovskiy NV; Nikitina VN; Semkina AS; Vlasova KY; Soldatov MA; Trigub AL; Skvortsov DA; Finko AV; Zyk NV; Sakharov DA; Majouga AG; Beloglazkina EK; Krasnovskaya OO
Inorg Chem; 2022 Sep; 61(37):14705-14717. PubMed ID: 36047922
[TBL] [Abstract][Full Text] [Related]
6. Pt(IV) Prodrugs with Non-Steroidal Anti-inflammatory Drugs in the Axial Position.
Spector DV; Pavlov KG; Akasov RA; Vaneev AN; Erofeev AS; Gorelkin PV; Nikitina VN; Lopatukhina EV; Semkina AS; Vlasova KY; Skvortsov DA; Roznyatovsky VA; Ul'yanovskiy NV; Pikovskoi II; Sypalov SA; Garanina AS; Vodopyanov SS; Abakumov MA; Volodina YL; Markova AA; Petrova AS; Mazur DM; Sakharov DA; Zyk NV; Beloglazkina EK; Majouga AG; Krasnovskaya OO
J Med Chem; 2022 Jun; 65(12):8227-8244. PubMed ID: 35675651
[TBL] [Abstract][Full Text] [Related]
7. BODI-Pt, a Green-Light-Activatable and Carboplatin-Based Platinum(IV) Anticancer Prodrug with Enhanced Activation and Cytotoxicity.
Yao H; Chen S; Deng Z; Tse MK; Matsuda Y; Zhu G
Inorg Chem; 2020 Aug; 59(16):11823-11833. PubMed ID: 32799491
[TBL] [Abstract][Full Text] [Related]
8. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
9. A Platinum(IV) Anticancer Prodrug Targeting Nucleotide Excision Repair To Overcome Cisplatin Resistance.
Wang Z; Xu Z; Zhu G
Angew Chem Int Ed Engl; 2016 Dec; 55(50):15564-15568. PubMed ID: 27736029
[TBL] [Abstract][Full Text] [Related]
10. Multi-Acting Mitochondria-Targeted Platinum(IV) Prodrugs of Kiteplatin with α-Lipoic Acid in the Axial Positions.
Savino S; Marzano C; Gandin V; Hoeschele JD; Natile G; Margiotta N
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 30011897
[TBL] [Abstract][Full Text] [Related]
11. Human Serum Albumin Conjugated Nanoparticles for pH and Redox-Responsive Delivery of a Prodrug of Cisplatin.
Shi H; Cheng Q; Yuan S; Ding X; Liu Y
Chemistry; 2015 Nov; 21(46):16547-54. PubMed ID: 26405808
[TBL] [Abstract][Full Text] [Related]
12.
Lee VEY; Lim ZC; Chew SL; Ang WH
Inorg Chem; 2021 Feb; 60(3):1823-1831. PubMed ID: 33464875
[TBL] [Abstract][Full Text] [Related]
13. Understanding the Role of Axial Ligands in Modulating the Biopharmaceutical Outcomes of Cisplatin(IV) Derivatives.
Date T; Kuche K; Ghadi R; Kumar P; Jain S
Mol Pharm; 2022 May; 19(5):1325-1337. PubMed ID: 35437994
[TBL] [Abstract][Full Text] [Related]
14. Targeting ROS-AMPK pathway by multiaction Platinum(IV) prodrugs containing hypolipidemic drug bezafibrate.
Qiao X; Gao YY; Zheng LX; Ding XJ; Xu LW; Hu JJ; Gao WZ; Xu JY
Eur J Med Chem; 2021 Nov; 223():113730. PubMed ID: 34388483
[TBL] [Abstract][Full Text] [Related]
15. A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes.
Ong JX; Lim CSQ; Le HV; Ang WH
Angew Chem Int Ed Engl; 2019 Jan; 58(1):164-167. PubMed ID: 30407697
[TBL] [Abstract][Full Text] [Related]
16. Beyond mere DNA damage: Recent progress in platinum(IV) anticancer complexes containing multi-functional axial ligands.
Deng Z; Zhu G
Curr Opin Chem Biol; 2023 Jun; 74():102303. PubMed ID: 37075513
[TBL] [Abstract][Full Text] [Related]
17. Recent Advances in Light-Controlled Activation of Pt(IV) Prodrugs.
Spector D; Pavlov K; Beloglazkina E; Krasnovskaya O
Int J Mol Sci; 2022 Nov; 23(23):. PubMed ID: 36498837
[TBL] [Abstract][Full Text] [Related]
18. Immuno-chemotherapeutic platinum(IV) prodrugs of cisplatin as multimodal anticancer agents.
Wong DY; Yeo CH; Ang WH
Angew Chem Int Ed Engl; 2014 Jun; 53(26):6752-6. PubMed ID: 24844571
[TBL] [Abstract][Full Text] [Related]
19. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
20. Abplatin
Li X; Zhang L; Li T; Li S; Wu W; Zhao L; Xie P; Yang J; Li P; Zhang Y; Xiao H; Yu Y; Zhao Z
J Nanobiotechnology; 2022 Jun; 20(1):258. PubMed ID: 35659243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
